Express Pharma
Home  »  Archive  »  IPM clocks Rs 6597 crores in April 2014

IPM clocks Rs 6597 crores in April 2014

0 18
Read Article

The Indian pharmaceutical market (IPM) clocked Rs 6597 crores in April 2014 and has seen a growth of 5.2 per cent. Amongst the top 10 companies, Mankind grew at 11.3 per cent followed by Lupin at 9.5 per cent and Sun Pharma at 8.6 per cent. 31 corporates have crossed the growth of IPM amongst top 50.

Amongst the top 50 corporates, Akumentis has the highest growth of 46.6 per cent followed by Ajanta at 39 per cent and Biocon at 35.3 per cent. Amongst the 11-20 ranked companies, Macleods has shown high growth at 25.6 per cent followed by Aristo at 18.7 per cent and Torrent at 14.5 per cent. Amongst the 50-75 ranked corporates, Corona shows high growth at 34.9 per cent followed by Apex at 33 per cent and Pharmed at 28.2 per cent.

Amongst the 76-100 ranked corporates, Gland Pharma has grown the fastest at 46.6 per cent. Indian companies have grown at 7.9 per cent versus -1.6 per cent for MNCs in April 2014. Amongst the top 50 in MNCs MSD grew the highest at 13.5 per cent, followed by Merck at 9.1 per cent and AstraZeneca at 5.5 per cent. Under the Non-NLEM category, Indian companies are growing at 10.4 per cent whereas MNCs at 1.6 per cent.

 
Withbonus units at full value (Val in Crs)
Val in Crs
Rank
MAT Apr -14
Apr-14
CORPORATE
MAT
MTH
Val (Cr)
MS%
GR%
Val (Cr)
MS%
GR%
IPM    
76055
100.00
5.9
6597
100.00
5.2
Abbott + Abbott HC + Novo
1
1
4880
6.42
4.2
414
6.28
0.0
Sun Pharma
2
2
4117
5.41
15.9
360
5.46
8.6
Cipla
3
3
3789
4.98
6.5
342
5.18
7.9
Zydus + Biochem
4
4
3359
4.42
7.8
291
4.41
6.0
Ranbaxy
5
6
2861
3.76
-1.8
229
3.47
-6.7
Glaxo
6
8
2730
3.59
-15.4
225
3.40
-11.2
Mankind
7
5
2699
3.55
5.0
245
3.71
11.3
Alkem + Cachet + Indchemie
8
9
2660
3.50
10.5
224
3.39
6.2
Lupin
9
7
2555
3.36
11.7
226
3.42
9.5
Pfizer
10
10
2218
2.92
3.0
197
2.98
4.2
Emcure + Zuventus
11
12
2142
2.82
14.7
183
2.77
11.6
Macleods
12
11
2018
2.65
10.3
190
2.89
25.6
Sanofi
13
15
1922
2.53
-0.1
159
2.41
-6.1
Intas
14
13
1896
2.49
7.7
167
2.54
3.6
Aristo
15
14
1851
2.43
13.4
162
2.46
18.7
Glenmark
16
16
1651
2.17
15.7
141
2.14
10.3

The DPCO 2013 containing molecules market was at –11.5 per cent whereas the non-DPCO market grew by eight per cent resulting in an overall growth of 5.2 per cent for April 2014. The DPCO 2013 portfolio for Pfizer de-grew at 26.9 per cent, GSK de-grew at 19.5 per cent and Ranbaxy de-grew by 25 per cent.

From therapy perspective, nine therapies have outgrown the IPM growth and five therapies have double digit growths. The respiratory market grew at 13.6 per cent, gastrointestinal market grew at 4.3 per cent whereas anti-infectives grew at 0.4 per cent. The anti-diabetic market grows at 14.1 per cent and cardiac at 4.8 per cent in chronic business. The derma market grew by 11.1 per cent.

From a regional perspective 13 regions have outgrown the IPM growth. The Vidarbha market grew the highest at 15.1 per cent followed by MP Market at 12.5 per cent. Three regions had negative growths in April 2014.

Val in Crs
MAT Apr 14
MNTH APR 14
Super Group
VAL IN CRS
GR%
VAL IN CRS
GR%
IPM
76055
5.9
6597
5.2
ANTI-INFECTIVES
12579
0.3
1006
0.4
CARDIAC
9451
7.9
842
4.8
GASTRO INTESTINAL
8530
5.4
774
4.3
VITAMINS / MINERALS / NUTRIENTS
6803
5.1
602
4.0
RESPIRATORY
5972
9.7
492
13.6
PAIN / ANALGESICS
5466
3.8
473
3.2
ANTI DIABETIC
5429
15.3
504
14.1
NEURO / CNS
4751
6.4
413
0.8
GYNAECOLOGICAL
4716
1.4
421
3.9
DERMA
4339
11.6
379
11.1
OPHTHAL / OTOLOGICALS
1359
8.0
128
7.9
HORMONES
1295
4.3
115
6.9
VACCINES
1104
-2.6
84
-13.1
ANTI-NEOPLASTICS
1054
29.1
96
26.9
BLOOD RELATED
927
3.8
79
3.9
OTHERS
886
3.9
81
5.9
ANTI MALARIALS
624
1.6
41
11.4
SEX STIMULANTS / REJUVENATORS
430
4.6
37
0.2
STOMATOLOGICALS
341
8.1
31
8.3

Amongst the top brands in the IPM, Glycomet GP (34.5 per cent), Galvus Met (28.8 per cent), Skinlite (22.9 per cent), Telma (22.4), Liv-52 (15.9 per cent) amongst top 25 Brands grew amongst the fastest over April-13.

A total of 123 brands launched in April 2014. Getlite, Straieout, Picnovit are the top NIs for the month of April 2014.

About PharmaTrac

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.

For more information, visit http://www.aiocd.net

Leave A Reply

Your email address will not be published.